Orexigen Announces Upcoming Data Presentations from the Open-Label Contrave Ignite Study at the Annual Meeting of the American Diabetes Association

Orexigen Therapeutics OREX announced today that two Contrave® (naltrexone HCI and bupropion HCI) abstracts will be presented at the upcoming annual meeting of the American Diabetes Association being held in Boston June 5 – 9, 2015 at the Boston Convention and Exposition Center. The abstracts are the first presentations of data from the randomized, open-label Ignite Study, which was designed to provide additional information regarding Contrave in combination with a behavioral modification program, compared to patients who received diet and exercise advice but who did not receive Contrave. Consistent with current labeling for recently approved anti-obesity medications, the 242 patients randomized into the study were required to achieve a certain amount of weight loss (at least 5% at week 16) and to not have a meaningful increase in blood pressure to remain on medication. The primary endpoint for this trial was change in body weight after 26 weeks in the per-protocol population. Secondary endpoints included the percentage of patients achieving at least 5% and 10% weight loss, waist circumference, lipids, and measures of glucose homeostasis, as well as a number of other key measures. Details on the presentation times are as follows: Date/Time: June 7, 2015, 12:00 – 2 PM Title: 1287-P. Efficacy of Naltrexone/Bupropion, Administered as Recommended in Clinical Practice, Compared with Usual Care Authors: Thomas Wadden, Brandon Walsh, Amy E. Halseth, Kevin Shan, Kenneth Fujioka Date/Time: June 7, 2015, 12:00 – 2 PM Title: 1194-P. Improvement in Patient-Assessed Quality of Life, Eating Behavior, and Sexual Function after 26 Weeks of Naltrexone/Bupropion Compared with Usual Care Authors: Kenneth Fujioka, Brandon Walsh, Amy E. Halseth, Kevin Shan, Thomas Wadden
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!